A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Trial Profile

A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Pembrolizumab (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Most Recent Events

    • 16 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 15 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top